Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications - Neurodegenerative -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (233)	6/5/2007 5:18:00 PM
From: tuck	Read Replies (1) \| Respond to of 448

>>Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon(TM) Alzheimer's Disease Study Tuesday June 5, 4:52 pm ET SAN FRANCISCO, June 5 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN - News) today announced that it will hold a teleconference at 8:30 a.m. Eastern time on Monday, June 11, to discuss top-line 12-month results from its randomized, double-blind, placebo-controlled Phase 2 clinical trial of Dimebon(TM), its lead product candidate, in Alzheimer's disease. Rachelle Doody, M.D., Ph.D., lead investigator for the study, will present the 12-month results for the first time at a scientific meeting at the 2007 Alzheimer's Association International Conference on Prevention of Dementia in Washington, D.C. Dr. Doody will present the data (abstract #S3-02-03, "Results of a One-Year Randomized, Placebo-Controlled Trial of Dimebon for the Treatment of Mild to Moderate Alzheimer's Disease") on Tuesday, June 12, at 10:00 a.m. Eastern time during the symposium session on "Emerging Compounds." Dr. Doody holds the Effie Marie Cain Chair in Alzheimer's Disease Research at the Alzheimer's Disease and Memory Disorders Center, Baylor College of Medicine in Houston. The Alzheimer's Association, sponsor of the Prevention of Dementia conference, has selected the Dimebon data for inclusion in a news briefing to be held during the conference. That news briefing, which will focus on Alzheimer's disease therapies and be open to credentialed reporters, writers or editors from recognized external print, broadcast, syndicated or online news organizations, will take place at 12:00 p.m. Eastern time on Monday, June 11. Teleconference/Webcast Details To participate in the live call on Monday, June 11, at 8:30 a.m. Eastern time by telephone, please dial 800-565-5442 from the U.S. or 913-312-1298 internationally. A telephone replay will be available for seven days following the conclusion of the call by dialing 888-203-1112 from the U.S. or 719-457-0820 for international callers and entering passcode 4782383. Individuals interested in listening to the live call via webcast may do so by visiting medivation.com. A replay of the webcast will be available on the Company's website for 30 days.<< snip Not sure if this will be binary, but it should cause some volatility, at the least. Last I checked, the options were strangely illiquid and unused. Cheers, Tuck